China, Nov. 4 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase II Study of Glofit-GemOx-P (Glofitamab, Gemcitabine, Oxaliplatin, and Pirtobrutinib) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600135840
Registration Time: 2026/11/03
Type: Interventional study
Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=342980
Published by HT Digital Content Services with permission from Health Daily Digest....